You are here

Illumina to pay US$7.1b for cancer test developer Grail

[BENGALURU] Gene sequencing company Illumina Inc will pay US$7.1 billion in cash and stock to buy cancer test startup Grail, the Wall Street Journal reported on Monday, citing people familiar with the matter.

Grail, which is developing a blood test to identify early-stage cancers, was founded by Illumina as a separate company in 2016 and is backed by founder Jeff Bezos and billionaire philanthropist Bill Gates.

The deal for Grail, in which Illumina is the biggest shareholder with a 14.6 per cent stake, is expected to be announced later, according to the report.

The company earlier this month filed for a US initial public offering, without disclosing the offering size.

Grail owners excluding Illumina will get US$3.1 billion in cash and shares in the gene-sequencer maker worth the remaining US$4 billion, the report said.

Your feedback is important to us

Tell us what you think. Email us at

Both Illumina and Grail did not immediately respond to Reuters' requests for comment.

Bloomberg News reported last week Illumina was nearing a deal for Grail.


BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to